Today, a brief rundown of news involving Novavax and Novo Nordisk, as well as updates from Relay Therapeutics, Takeda and Tubulis that you may have missed.

今天，简要介绍一下Novax和Novo Nordisk的新闻，以及您可能错过的Relay Therapeutics、武田和Tubulis的最新消息。

Novavax has agreed to sell a manufacturing plant in Bohumil, Czech Republic, to Danish drugmaker Novo Nordisk for $200 million. The factory, which can produce recombinant protein, will be transferred to Novo along with its supporting buildings, staff and related infrastructure when the deal closes. In addition to boosting Novavax’s cash holdings, the deal will reduce the vaccine maker’s annual operating costs by approximately $80 million.

诺瓦克斯已同意以2亿美元的价格将位于捷克共和国博胡米尔的一家制造厂出售给丹麦制药商诺和诺德。这家可以生产重组蛋白的工厂将在交易结束时连同配套建筑、员工和相关基础设施一起移交给诺沃。除了增加Novax的现金持有量外，该交易还将使疫苗制造商的年度运营成本降低约8000万美元。

Novo, which has been investing heavily in manufacturing to meet demand for its weight loss and diabetes therapies, is in the midst of closing another deal to acquire three Catalent facilities. — Delilah Alvarado.

Novo一直在大力投资制造业，以满足其减肥和糖尿病治疗的需求，目前正在达成另一笔收购三家Catalent工厂的交易黛利拉·阿尔瓦拉多。

Elevar Therapeutics, a majority-owned subsidiary of Korea’s HLB Co., is paying $75 million to license a medicine developed by Relay Therapeutics for a form of bile duct cancer. The upfront fee gives Elevar global development and commercialization rights to the drug, called lirafugratinib. Trial data previously suggested lirafugratinib could be more effective than existing options in treating cholangiocarcinoma with certain genetic mutations.

韩国HLB公司的控股子公司Elevator Therapeutics正在支付7500万美元，以授权Relay Therapeutics开发的一种治疗胆管癌的药物。预付费用为该药物提供了更高的全球开发和商业化权利，称为利拉夫拉替尼。先前的试验数据表明，利拉夫拉替尼在治疗具有某些基因突变的胆管癌方面可能比现有选择更有效。

A study meant to support an application for accelerated approval is ongoing. — Ned Pagliarulo.

一项旨在支持加速批准申请的研究正在进行中内德·帕利亚鲁洛。

Roivant Sciences reported Tuesday that a study run by one of its subsidiaries, Kinevant Sciences, failed to show a benefit for the company’s antibody treatment for chronic active pulmonary sarcoidosis. As a result, further development of the drug, dubbed namilumab, in sarcoidosis will be halted. Analysts had viewed this program as “high-risk, high-reward,” and ascribed little value to its development.

Roivant Sciences周二报道，其子公司Kinevant Sciences进行的一项研究未能显示该公司对慢性活动性肺结节病的抗体治疗有益。因此，在结节病中被称为纳米鲁单抗的药物的进一步开发将停止。分析人士认为这项计划是“高风险、高回报”的，并认为其发展没有什么价值。

Shares in Roivant fell by nearly 3% Tuesday. — Ned Pagliarulo.

Roivant股价周二下跌近3%。-内德·帕利亚鲁洛。

Takeda will pay $200 million to secure rights outside of China, Hong Kong and Macau to an experimental blood disease drug developed by Cambridge, Massachusetts-based Keros Therapeutics. The drug, called elritercept, is in two Phase 2 trials involving people with myelodysplastic syndromes or myelofibrosis.

武田将支付2亿美元，以获得位于马萨诸塞州剑桥市的Keros Therapeutics开发的一种实验性血液病药物在中国、香港和澳门以外地区的使用权。这种名为elritercept的药物正在进行两项2期临床试验，涉及骨髓增生异常综合征或骨髓纤维化患者。

A Phase 3 study is set to begin “soon,” according to the companies. “The addition of elritercept further bolsters our oncology pipeline and introduces a potential future growth driver for Takeda,” said Teresa Bitetti, head of Takeda’s oncology business unit, in a Tuesday statement. — Ned Pagliarulo.

据这些公司称，第三阶段研究将“很快”开始。“elritercept的加入进一步巩固了我们的肿瘤学渠道，并为武田带来了潜在的未来增长动力，”武田肿瘤学业务部门负责人TeresaBitetti在周二的声明中表示内德·帕利亚鲁洛。

Antibody-drug conjugate maker Tubulis announced Tuesday it has struck a deal with Gilead Sciences to find new cancer medicines. Under terms of the collaboration, Gilead paid the German biotech $20 million upfront in exchange for access to its technology and an option to license a program for an additional $30 million fee.

抗体药物偶联物制造商Tubulis周二宣布，已与吉利德科学公司达成协议，寻找新的抗癌药物。根据合作条款，吉利德向这家德国生物技术公司支付了2000万美元的预付款，以换取其技术的使用权和一项额外3000万美元费用的项目许可选择权。

If successful, Tubulis stands to gain as much as $415 million in development and commercialization milestone payments, as well as royalties. — Gwendolyn Wu.

如果成功，Tubulis将获得多达4.15亿美元的开发和商业化里程碑付款，以及版税Gwendolyn Wu。